616 related articles for article (PubMed ID: 30648327)
1. Diagnostic performance of MR for hepatocellular carcinoma based on LI-RADS v2018, compared with v2017.
Ren AH; Zhao PF; Yang DW; Du JB; Wang ZC; Yang ZH
J Magn Reson Imaging; 2019 Sep; 50(3):746-755. PubMed ID: 30648327
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic Performance of LI-RADS Version 2018, LI-RADS Version 2017, and OPTN Criteria for Hepatocellular Carcinoma.
Kierans AS; Song C; Gavlin A; Roudenko A; Lu L; Askin G; Hecht EM
AJR Am J Roentgenol; 2020 Nov; 215(5):1085-1092. PubMed ID: 32877248
[No Abstract] [Full Text] [Related]
3. LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium-enhanced MRI.
Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH
Radiology; 2019 Sep; 292(3):655-663. PubMed ID: 31310175
[TBL] [Abstract][Full Text] [Related]
4. Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?
Zhang T; Huang ZX; Wei Y; Jiang HY; Chen J; Liu XJ; Cao LK; Duan T; He XP; Xia CC; Song B
World J Gastroenterol; 2019 Feb; 25(5):622-631. PubMed ID: 30774276
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the diagnostic performance of the 2017 and 2018 versions of LI-RADS for hepatocellular carcinoma on gadoxetic acid enhanced MRI.
Ko A; Park HJ; Lee ES; Park SB; Kim YK; Choi SY; Ahn S
Clin Radiol; 2020 Apr; 75(4):319.e1-319.e9. PubMed ID: 31858990
[TBL] [Abstract][Full Text] [Related]
6. Liver Imaging Reporting and Data System Version 2018: Impact on Categorization and Hepatocellular Carcinoma Staging.
Chernyak V; Flusberg M; Berman J; Fruitman KC; Kobi M; Fowler KJ; Sirlin CB
Liver Transpl; 2019 Oct; 25(10):1488-1502. PubMed ID: 31344753
[TBL] [Abstract][Full Text] [Related]
7. Data-Driven Modification of the LI-RADS Major Feature System on Gadoxetate Disodium-Enhanced MRI: Toward Better Sensitivity and Simplicity.
Jiang H; Song B; Qin Y; Wei Y; Konanur M; Wu Y; Zaki IH; McInnes MDF; Lafata KJ; Bashir MR
J Magn Reson Imaging; 2022 Feb; 55(2):493-506. PubMed ID: 34236120
[TBL] [Abstract][Full Text] [Related]
8. Intraindividual Comparison of Contrast-Enhanced Ultrasound Using Perfluorobutane With Modified Criteria Versus CT/MRI LI-RADS Version 2018 for Diagnosing HCC in High-Risk Patients.
Li L; Mao S; Wang J; Zheng W; Shen J; Clevert DA; Zhou J
AJR Am J Roentgenol; 2023 May; 220(5):682-691. PubMed ID: 36382914
[No Abstract] [Full Text] [Related]
9. What proportion of LI-RADS 5 observations reported in clinical practice do not meet LI-RADS 5 criteria?
Ghadimi M; Birnbaum J; Kamel IR; Sirlin CB; Chernyak V
Eur Radiol; 2022 May; 32(5):3327-3333. PubMed ID: 34807269
[TBL] [Abstract][Full Text] [Related]
10. Hepatic Steatosis Has No Effect in Diagnosis Accuracy of LI-RADS v2018 Categorization of Hepatocellular Carcinoma in MR Imaging.
Yao S; Wei Y; Ye Z; Chen J; Duan T; Zhang Z; Song B
J Magn Reson Imaging; 2024 Jun; 59(6):2060-2070. PubMed ID: 34121266
[TBL] [Abstract][Full Text] [Related]
11. Critical analysis of major and ancillary features of LI-RADS v2018 in the differentiation of small (≤ 2 cm) hepatocellular carcinoma from dysplastic nodules with gadobenate dimeglumine-enhanced magnetic resonance imaging.
De Gaetano AM; Catalano M; Pompili M; Marini MG; Rodríguez Carnero P; Gullì C; Infante A; Iezzi R; Ponziani FR; Cerrito L; Marrone G; Giuliante F; Ardito F; Rapaccini GL; Vecchio FM; Giraldi L; Manfredi R;
Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7786-7801. PubMed ID: 31599447
[TBL] [Abstract][Full Text] [Related]
12. Modifying LI-RADS on Gadoxetate Disodium-Enhanced MRI: A Secondary Analysis of a Prospective Observational Study.
Jiang H; Song B; Qin Y; Konanur M; Wu Y; McInnes MDF; Lafata KJ; Bashir MR
J Magn Reson Imaging; 2022 Aug; 56(2):399-412. PubMed ID: 34994029
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic Performance of CT/MRI Liver Imaging Reporting and Data System v2017 for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.
Lee S; Kim SS; Roh YH; Choi JY; Park MS; Kim MJ
Liver Int; 2020 Jun; 40(6):1488-1497. PubMed ID: 32145134
[TBL] [Abstract][Full Text] [Related]
14. Does quantitative assessment of arterial phase hyperenhancement and washout improve LI-RADS v2018-based classification of liver lesions?
Stocker D; Becker AS; Barth BK; Skawran S; Kaniewska M; Fischer MA; Donati O; Reiner CS
Eur Radiol; 2020 May; 30(5):2922-2933. PubMed ID: 32020398
[TBL] [Abstract][Full Text] [Related]
15. Validation of Liver Imaging Reporting and Data System 2017 (LI-RADS) Criteria for Imaging Diagnosis of Hepatocellular Carcinoma.
Kierans AS; Makkar J; Guniganti P; Cornman-Homonoff J; Lee MJ; Pittman M; Askin G; Hecht EM
J Magn Reson Imaging; 2019 Jun; 49(7):e205-e215. PubMed ID: 30257054
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic accuracy of prospective application of the Liver Imaging Reporting and Data System (LI-RADS) in gadoxetate-enhanced MRI.
Kim YY; An C; Kim S; Kim MJ
Eur Radiol; 2018 May; 28(5):2038-2046. PubMed ID: 29230525
[TBL] [Abstract][Full Text] [Related]
17. Hepatocellular carcinoma (HCC) versus non-HCC: accuracy and reliability of Liver Imaging Reporting and Data System v2018.
Ludwig DR; Fraum TJ; Cannella R; Ballard DH; Tsai R; Naeem M; LeBlanc M; Salter A; Tsung A; Shetty AS; Borhani AA; Furlan A; Fowler KJ
Abdom Radiol (NY); 2019 Jun; 44(6):2116-2132. PubMed ID: 30798397
[TBL] [Abstract][Full Text] [Related]
18. White paper of the Society of Abdominal Radiology hepatocellular carcinoma diagnosis disease-focused panel on LI-RADS v2018 for CT and MRI.
Elsayes KM; Kielar AZ; Elmohr MM; Chernyak V; Masch WR; Furlan A; Marks RM; Cruite I; Fowler KJ; Tang A; Bashir MR; Hecht EM; Kamaya A; Jambhekar K; Kamath A; Arora S; Bijan B; Ash R; Kassam Z; Chaudhry H; McGahan JP; Yacoub JH; McInnes M; Fung AW; Shanbhogue K; Lee J; Deshmukh S; Horvat N; Mitchell DG; Do RKG; Surabhi VR; Szklaruk J; Sirlin CB
Abdom Radiol (NY); 2018 Oct; 43(10):2625-2642. PubMed ID: 30155697
[TBL] [Abstract][Full Text] [Related]
19. Increasing the sensitivity of LI-RADS v2018 for diagnosis of small (10-19 mm) HCC on extracellular contrast-enhanced MRI.
Chen J; Kuang S; Zhang Y; Tang W; Xie S; Zhang L; Rong D; He B; Deng Y; Xiao Y; Shi W; Fowler K; Wang J; Sirlin CB
Abdom Radiol (NY); 2021 Apr; 46(4):1530-1542. PubMed ID: 33040166
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic Performance of 2018 KLCA-NCC Practice Guideline for Hepatocellular Carcinoma on Gadoxetic Acid-Enhanced MRI in Patients with Chronic Hepatitis B or Cirrhosis: Comparison with LI-RADS Version 2018.
Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH
Korean J Radiol; 2021 Jul; 22(7):1066-1076. PubMed ID: 33739633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
